BeyondSpring posts corporate presentation spotlighting plinabulin immune-modulating cancer therapy pipeline

BeyondSpring Inc.

BeyondSpring Inc.

BYSI

0.00
  • BeyondSpring outlined late-stage plans for plinabulin, positioning it for non-squamous NSCLC following PD-1/L1 inhibitor progression.
  • DUBLIN-3 Phase 3 (n=559) showed OS HR 0.82; median OS 10.5 months vs 9.4 months for docetaxel; p=0.0399.
  • Grade 4 neutropenia fell to 22.3% from 43.5% across cycles; exposure-adjusted grade 4 event rate RR 0.55; p<0.0001.
  • Mechanism-enriched post-hoc subset showed median OS 15.8 months vs 11.7 months; OS HR 0.55.
  • Planned DUBLIN-4 confirmatory Phase 3 targets post-PD-1/L1 non-squamous NSCLC with PFS of at least 3 months.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BeyondSpring Inc. published the original content used to generate this news brief on July 09, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.